These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 22409779

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Emergence of extended-spectrum β-lactamase producing Enterobacter spp. in patients with bacteremia in a tertiary hospital in southern Brazil.
    Nogueira Kda S, Paganini MC, Conte A, Cogo LL, Taborda de Messias Reason I, da Silva MJ, Dalla-Costa LM.
    Enferm Infecc Microbiol Clin; 2014 Feb; 32(2):87-92. PubMed ID: 23587705
    [Abstract] [Full Text] [Related]

  • 3. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
    Freeman JT, McBride SJ, Nisbet MS, Gamble GD, Williamson DA, Taylor SL, Holland DJ.
    Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
    [Abstract] [Full Text] [Related]

  • 4. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM, Askin G, Christos P.
    Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
    [Abstract] [Full Text] [Related]

  • 5. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.
    Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, Cosgrove SE, Carroll KC.
    Clin Infect Dis; 2013 Sep; 57(6):781-8. PubMed ID: 23759352
    [Abstract] [Full Text] [Related]

  • 6. Risk factors associated with extended-spectrum β-lactamase-producing Enterobacteriaceae nosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis.
    Muro S, Garza-González E, Camacho-Ortiz A, González GM, Llaca-Díaz JM, Bosques F, Rositas F.
    Chemotherapy; 2012 Sep; 58(3):217-24. PubMed ID: 22814216
    [Abstract] [Full Text] [Related]

  • 7. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
    Henshke-Bar-Meir R, Yinnon AM, Rudensky B, Attias D, Schlesinger Y, Raveh D.
    Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
    [Abstract] [Full Text] [Related]

  • 8. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS, Lee MH, Leu HS.
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
    Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T.
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K, Wong SS, Lin LC, Tsai CR, Chen LC, Huang CH.
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [Abstract] [Full Text] [Related]

  • 19. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE, Antibacterial Resistance Leadership Group.
    Clin Infect Dis; 2015 May 01; 60(9):1319-25. PubMed ID: 25586681
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.